Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AGIOS PHARMACEUTICALS, INC. (AGIO) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/28/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/21/2023 4 Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 6,395 shares @ $26.28, valued at $168.1k
08/15/2023 4 Ballal Rahul D. (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Exercised 2,302 restricted stock units @ $0
08/15/2023 4 Smith Cynthia (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Exercised 2,302 restricted stock units @ $0
08/11/2023 4 Foster-Cheek Kaye I (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 25,000 shares @ $25.9555, valued at $648.9k
Exercised 25,000 options to buy @ $18.09, valued at $452.3k
08/10/2023 4 Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 10,178 shares @ $25.48, valued at $259.3k
Exercised 22,691 restricted stock units @ $0
08/09/2023 4 Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 2,918 shares @ $25.3927, valued at $74.1k
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Agios Reports Business Highlights and Second Quarter 2023 Financial Results –Announced Positive Results from Phase 2 Portion of the RISE UP Pivotal Study of Mitapivat in Sickle Cell Disease&#59; On Track to Enroll First Patient in Phase 3 Portion of the Study in Q4 2023"
08/02/2023 4 Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 1,232 shares @ $26.26, valued at $32.4k
Exercised 4,150 restricted stock units @ $0
07/06/2023 4 Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Granted 25,124 restricted stock units @ $0
06/30/2023 4 Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 1,707 shares @ $28.36, valued at $48.4k
Exercised 5,750 options to buy @ $0
06/30/2023 4 FOUSE JACQUALYN A (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 10,718 shares @ $28.36, valued at $304k
Exercised 23,900 options to buy @ $0
06/30/2023 4 Gheuens Sarah (Chief Medical Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 1,707 shares @ $28.36, valued at $48.4k
Exercised 5,750 options to buy @ $0
06/30/2023 4 Goff Brian (CEO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 11,449 shares @ $28.36, valued at $324.7k
Exercised 25,528 options to buy @ $0
06/30/2023 4 Jones Cecilia (CFO) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 1,597 shares @ $28.36, valued at $45.3k
Exercised 5,380 options to buy @ $0
06/30/2023 4 Milanova Tsveta (Chief Commercial Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 1,618 shares @ $28.36, valued at $45.9k
Exercised 5,449 options to buy @ $0
05/25/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/19/2023 8-K Quarterly results
04/05/2023 4 Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 16,363 shares @ $22.85, valued at $373.9k
Exercised 16,363 options to buy @ $9.05, valued at $148.1k
03/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/15/2023 4 Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 18,333 shares @ $22.47, valued at $411.9k
Sold 1,667 shares @ $22.72, valued at $37.9k
Exercised 20,000 options to buy @ $9.05, valued at $181k
03/07/2023 4 Washburn Theodore James Jr. (Principal Accounting Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 504 shares @ $24.29, valued at $12.2k
03/01/2023 4 Schenkein David P (Director) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Sold 20,000 shares @ $25.37, valued at $507.4k
Exercised 20,000 options to buy @ $9.05, valued at $181k
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Quarterly results
Docs: "Agios Reports Fourth Quarter and Full Year 2022 Financial Results – Completed Enrollment in Phase 2 RISE UP Study of PYRUKYND® in Sickle Cell Disease –"
02/14/2023 4 Burns James William (Chief Legal Officer) has filed a Form 4 on AGIOS PHARMACEUTICALS, INC.
Txns: Paid exercise price by delivering 643 shares @ $28.44, valued at $18.3k
Exercised 1,834 restricted stock units @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy